NELFCD and breast cancer: We demonstrated in vitro that ERpos/HER-2pos breast cancer lines were less susceptible to Th1 cytokines than their ERneg/HER-2pos counterparts, and this disparity in sensitivity could be ablated by the addition of anti-estrogen drugs coincident with cytokine exposure.